SELB

SEL-212

Chronic Refractory Gout

Stage (next event)

Expected Date

Phase 3

Catalyst Info & Data Links

TITLE:  SEL-212 in Chronic Refractory Gout 

  • ClinicalTrial.gov (NCT04596540): A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II (DISSOLVE II)


  • ClinicalTrial.gov (NCT04513366): A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy (DISSOLVE I)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 3 Data


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA

PRESS RELEASES


Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • SEL-212 is a novel combination product candidate designed to sustain control of serum uric acid (SUA) levels in patients with chronic refractory gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. SEL-212 consists of pegadricase, Selecta’s proprietary pegylated uricase, co-administered with ImmTOR, designed to mitigate the formation of anti-drug antibodies (ADAs). ADAs develop due to unwanted immune responses to biologic medicines, rendering these therapies less potent, which remains an issue across multiple therapeutic modalities and disease states including chronic refractory gout.

MARKET

  • Affecting approximately 160,000 people in the United States, chronic refractory gout is a painful and severe form of inflammatory arthritis that can lead to bone erosions and joint deformities resulting in loss of function and disability (Learn more HERE)

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon